Medical Oncologist at Gazi University| PhD in Medical Biology&Genetics| Member of ASCO TECAG and ECO YCP SC-2026 IDEA Awardee| JCO GO Editorial Fellow
- Tweets 236
- Following 781
- Followers 217
- Likes 1,525
Pinned Tweet
Advocacy Starts With Us: What I Learned About Advocacy at ASCO25 | ASCO Connection connection.asco.org/do/advoc… @ASCO #ASCconnection #advocacy
1
11
1,041
İmdat Eroğlu retweeted
It hard to explain why 1 trial with gem/cis +/-PD(L)1 (NIAGARA) is +ve for EFS/OS and 2 very similar trials (presented today) are negative in MIBC. Potentially NIAGARA has the highest risk population, not all respond to IO and the maintenance phase the most effect- but the OS of gem/cis pembro HR of 1 is concerning. This reflects what we saw in metastatic disease with contradictory results for the big combination trials. Overall EVP looks better and more consistent #ESMO26 @myESMO @Annals_Oncology @OncoAlert
4
69
175
10,889
İmdat Eroğlu retweeted
#ESMO26 has started a bit early this year for me! I am in Madrid to join @myESMO ESMO Leadership and Career Development Award education for two days before getting started #ESMO26 !
Many thanks to ESMO for the opportunity and supporting our project as well! I do believe it will add more to my career path as a physician-scientist! and I know @myESMO has only ultimate goal...beating cancer!
@TeresaSAmaral @FAndreMD @curijoey @AndresC27622123 @DrYukselUrun @Silke_Gillessen @DrChoueiri
3
6
37
1,742
Submit your paper for this special issue. Cancer Cell Metabolism—Potential Target for Cancer Therapy mdpi.com/si/291539 #mdpimetabolites @MetabolitesMDPI aracılığıyla
1
1
124
İmdat Eroğlu retweeted
More evidence for Nectin4 as a biomarker for EV in @EUplatinum
In 1L EV+P, high Nectin4 RNA expression was associated with ⬆️ORR and OS but this was not seen with Pembro alone.
Data on membranous expression & amplification might be useful.
@OncoAlert
europeanurology.com/article/…
1
21
48
5,675
İmdat Eroğlu retweeted
🥬Could diet influence #ProstateCancer progression during active surveillance?
Greater adherence to a plant-based diet was associated with a 42% lower risk of disease upgrading in a prospective cohort
🔹Drs. Zhuo Tony Su & Christian P. Pavlovich | #AUA26
ascopost.com/news/september-…
5
11
2,082
Ever wonder how heterogeneity defines bladder cancer subtypes?
Ha and Hsieh Lab postdoctoral fellows @pushpa_itagi and Samantha Schuster @fredhutch did, leading to a deep study of bladder cancer clonality, evolution, and heterogeneity published @Nature
nature.com/articles/s41586-0…
13
57
171
38,524
Updated ASCO Guideline: Systemic Therapy in Patients w/ Metastatic Castration-Resistant Prostate Cancer. Including evidence from prev. trials along w/ 2 additional trials & updates algorithms for biomarker-informed treatment selection. Read the guideline: bit.ly/4xZaiV4
11
14
5,877
İmdat Eroğlu retweeted
🎉🎉🎉Honoured and deeply grateful to share that I have been selected as a 2026 recipient of the @myESMO "ESMO Leadership and Career Development Award LDCA", alongside an exceptional group of highly valued and inspiring researchers from around the world. This recognition is a tremendous privilege and a meaningful milestone in my academic and professional journey.
I sincerely thank @myESMO for this prestigious opportunity and for supporting the next generation of leaders in oncology.
Very special thanks to my great mentors @DrChoueiri @DrYukselUrun and Prof. Hakan Akbulut for their lifelong support!
@TeresaSAmaral @ravikanesvaran @OncoAlert @AnkaraUni @AUTF_DEKANLIK
6
10
100
8,043
İmdat Eroğlu retweeted
An important perspective on the evolving concept of oligometastatic ovarian cancer.
The ESTRO–EORTC OligoCare classification provides a valuable framework, but ovarian cancer, particularly high-grade serous disease, poses unique challenges due to its pattern of peritoneal dissemination.
This article highlights the need for ovarian cancer–specific definitions and a multidisciplinary approach integrating systemic therapy, surgery, and metastasis-directed radiotherapy.
An interesting step toward more precise patient selection and future clinical trial design.
@TheLancetOncol
thelancet.com/journals/lanon…
#OvarianCancer #OligometastaticDisease #GynecologicOncology #Radiotherapy #MedicalOncology #PrecisionOncology
1
1
38
İmdat Eroğlu retweeted
“Natural” does not always mean safe, especially during cancer treatment.
A newly published JAMA Oncology Patient Page highlights an issue we frequently encounter in daily oncology practice: the growing use of supplements and “wellness” products during cancer care.
Patients may turn to herbal supplements, high-dose vitamins, detox products, or so-called “immune boosters” hoping to improve energy, reduce side effects, or support their treatment. Yet some of these products may:
• reduce the effectiveness of anticancer treatments
• alter drug metabolism through the liver or kidneys
• increase bleeding risk
• worsen treatment-related adverse effects
Importantly, the message is not that all supplements are harmful.
The key question is much more clinically relevant:
Is this product safe, evidence-based, and appropriate for this specific patient and treatment?
In oncology, we routinely ask patients about prescription medications. Perhaps we should be equally consistent in asking about vitamins, herbal products, supplements, and other wellness products.
Because what is marketed as “natural” is not necessarily harmless, and what seems supportive may sometimes interfere with effective cancer treatment.
A simple question can make a difference:
“Are you taking any supplements or wellness products that we haven’t discussed?”
jamanetwork.com/journals/jam…
@JAMAOnc
#Oncology #CancerCare #MedicalOncology #PatientSafety #SupportiveCare #EvidenceBasedMedicine
1
1
31
İmdat Eroğlu retweeted
Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4.
Read the full article. bit.ly/4wRpUsT
#ProstateCancer #pcsm
3
6
2,016
İmdat Eroğlu retweeted
Updated results from the phase III OlympiA trial provide compelling long-term evidence for adjuvant olaparib in patients with germline BRCA1/2-associated, high-risk HER2-negative early breast cancer.
At a median follow-up of 6.1 years, one year of adjuvant olaparib continued to demonstrate clinically meaningful improvements in:
• IDFS: HR 0.65
• DDFS: HR 0.65
• OS: HR 0.72
• 6-year OS: 87.5% vs 83.2%
Importantly, the benefit remained consistent across key subgroups, including patients with high-risk hormone receptor-positive disease, with no increase in MDS/AML.
These mature data further reinforce the role of germline BRCA1/2 testing and PARP inhibition as integral components of precision treatment in high-risk early breast cancer.
annalsofoncology.org/article…
@Annals_Oncology
#BreastCancer #BRCA #Olaparib #PARPInhibitors #PrecisionOncology #MedicalOncology #OlympiA
1
1
62
İmdat Eroğlu retweeted
Improving Prognostic Stratification for Glioblastoma Without Universal Molecular Testing - İmdat Eroğlu
@imdat_eroglu
oncodaily.com/voices/imdat-e…
1
1
167
Check out our recent paper published at Future Oncology @tandfonline @tandfnewsroom @tandfMediaArts
tandfonline.com/doi/full/10.…
1
4
198
İmdat Eroğlu retweeted
Progress in Colorectal Cancer Mortality Across 48 Countries: The Impact of Screening and Early Detection.
Read the full article. bit.ly/4b8VlGr
#ColorectalCancer #crcsm
1
4
710
İmdat Eroğlu retweeted
Excited and grateful to begin my fellowship at MD Anderson Cancer Center.
Looking forward to learning, growing, and serving patients. Thankful to everyone who has helped me reach this point.
19
9
168
20,896
İmdat Eroğlu retweeted
Cancer Frequencies and Screening in Individuals with Down Syndrome: A Comprehensive Nationwide Cross-Sectional Analysis.
Read the full article. bit.ly/4vVsbDe
2
4
319
İmdat Eroğlu retweeted
Integrating Metronomic Therapy with Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS).
Read the full article. bit.ly/44anHwb
2
2
255
İmdat Eroğlu retweeted
Exercise as Treatment, Not an Adjunct: Rethinking Colorectal Cancer Survivorship in Global Oncology.
Read the full article. bit.ly/4eR6YmA
#ColorectalCancer #crcsm
2
4
248
İmdat Eroğlu retweeted
Targeting Inequities: Addressing Lung Cancer Care Challenges in Africa Through Drug Access, Radiotherapy, and Surgical Innovations.
Read the full article. bit.ly/4eOKNgu
#LungCancer #lcsm
1
1
219